Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ARID1A Q1327* |
| Therapy | Olaparib |
| Indication/Tumor Type | pancreatic ductal adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ARID1A Q1327* | pancreatic ductal adenocarcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) treatment resulted in an objective response with 40% decrease in the diameter of the lesion and a progression-free survival of at least 13 months in a patient with pancreatic ductal adenocarcinoma harboring ARID1A Q1327* along with KRAS G12R, TP53 R273C, and CBL A463V (PMID: 31764178). | 31764178 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (31764178) | Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation. | Full reference... |